Israel Active

Israeli biotech Nucleai (reported previously) has progressed from merely analyzing biopsies. It now uses its computer vision and machine learning to study the characteristics of tumors, helping predict which cancer patients will respond to which immunotherapy medication.

There are some “nectin” proteins that help cancer cells evade the immune system. Israel’s Nectin Therapeutics (at the Hebrew University of Jerusalem) places novel monoclonal antibodies into these nectins to stimulate the immune system and help it fight cancers in solid tissue and in the bloodstream.  

Israel’s CAPS Medical has developed a small disposable catheter that can reach deep inside the body to deliver cold atmospheric plasma (CAP). The plasma is a stream of high-energy ionized gas that kills solid cancer cells and triggers a tumor-destroying immune response without harming healthy cells.

Israel’s Council for Higher Education and philanthropic foundations have selected 25 research projects to share NIS 9 million from their “killCorona” program to help combat Covid-19. The projects include diagnostics, vaccines, treatments for severe cases and curbing the spread of the virus.

One of the treatments being developed by Israel’s Can-Fite is CF-101 (Piclidenoson) which is in Phase 2 & 3 trials for psoriasis, rheumatoid arthritis and other diseases.  Can-Fite is shortly to commence a Phase 2 trial of CF-101 on Covid-19 patients.

Researchers at Tel Aviv University have developed a serological test that from one blood sample can, for the first time, identify all three of the key antibodies that counter Covid-19. The test is extremely sensitive and accurate to around 98-99 percent, better than current tests.

Israel’s Nanox (reported previously) has signed multiple new deals to deploy over 1000 of its mobile X-ray devices to , and .  Previous deployments include to Japan, Australia, New Zealand, Norway, South Korea and Vietnam.

An exciting article about a United Hatzalah paramedic who, on the eve of her final chemistry exam, rushed to save the life of a heart-attack victim.

The latest Ben-Gurion Briefing, “Autism Research and Treatment” featured 4 leading Israeli experts from Ben-Gurion University and Soroka University Medical Center. They discussed whether early autism diagnosis can lead to the eradication of symptoms of autism later in life.

At its Israeli R&D center, C2i Genomics has developed a personalized, real-time solution for monitoring recurrence and treatment response for various types of solid cancers. It employs a breakthrough tumor DNA pattern recognition approach for liquid biopsy.